Document Title
Should Remdesivir Be Used for the Treatment of Patients with COVID-19? Rapid, Living Practice Points from the American College of Physicians
Synopsis
ACP issued its fifth and final living, rapid Practice Points regarding the use of remdesivir in hospitalized patients with COVID-19. The updated Practice Points are based on a review of the most up-to-date published data available on the benefits and harms of remdesivir and whether those benefits and harms vary by symptom duration, disease severity, and treatment duration.
Author
Reyna Howkins
Keywords
Remdesivir, COVID-19, SARS-CoV-2, mechanical ventilation, extracorporeal membrane oxygenation, ECMO, respiratory failure, antiviral, practice points,
Creation Date
Modified Date
Pages
1
Document
practice_point_use_of_remdesivir_treating_covid19_2022.pdf
Adobe Metadata
{"Author":"Reyna Howkins","Creator":"Microsoft\u00ae Word for Microsoft 365","CreationDate":"2022-02-28T14:12:09-05:00","ModDate":"2022-02-28T14:12:51-05:00","Producer":"Microsoft\u00ae Word for Microsoft 365","Title":"Should Remdesivir Be Used for the Treatment of Patients with COVID-19? Rapid, Living Practice Points from the American College of Physicians","Subject":"","Keywords":"Remdesivir, COVID-19, SARS-CoV-2, mechanical ventilation, extracorporeal membrane oxygenation, ECMO, respiratory failure, antiviral, practice points,","Pages":1}
Document Type
Guideline
Year
2022